Abstract
Introduction

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of non-Hodgkin lymphoma infiltrating into subcutaneous tissue. Systemic symptoms are variable and some patients present with hemophagocytic syndrome (HPS)
with pancytopenia, fever, and hepatosplenomegaly. The treatment strategy for SPTCL is not standardized, and this disorder has a high mortality rate despite the use of aggressive chemotherapy. Recently, several patients with SPTCL were reported to respond dramatically to cyclosporin A treatment (1) . We have successfully used prednisolone and cyclosporin A to treat a patient with SPTCL. This report provides review of our case and discusses the rational for using cyclosporin A. i g u r e 1 . Ab d o mi n a l CT : s i g n i f i c a n t t h i c k e n i n g o f s u b c u t an e o u s t i s s u e c o mp a t i b l e wi t h r e g i o n o f h u g e t u mo r i n t h e r i g h t i n f r a c o s t a l r e g i o n . (Fig. 3) . Immunofluorescent staining (Fig. 4) F i g u r e 4 . I mmu n o f l u o r e s c e n t s t a i n i n g ( I mmu n o f l u o r e s c e n t s t a i n , × 2 0 0 ) s h o we d ( A) CD3 ( + ) , ( B ) CD4 ( -) , ( C) CD8 ( + ) l y mp h o c y t e s a n d ( D) T -c e l l i n t r a c e l l u l a r a n t i g e n wa s p o s i t i v e . (Fig. 5) 
Case Report
apy. His trough range of cyclosporin A was maintained between 60-70 nmol/l. Combination therapy of prednisolone and cyclosporin A not only improved HPS but also alleviated SPTCL, and the subcutaneous nodule diminished to 1 cm in diameter
Discussion
The distinctive clinicopathological features of a T-cell lymphoma involving the subcutaneous tissue were described in 1991 by Gonzalez et al (2). Immunophenotypic and genotypic findings confirmed the T-cell phenotype as well as monoclonality of this lesion. Thus, the T-cell origin of this lymphoma has been proved and in 1994, this disease was identified as a provisional entity in the Revised European
American classification of lymphoid neoplasmas and named SPTCL (3). In the past, it is likely that many cases of SPTCL were reported as Weber-Christian disease or cytophagic histiocytic panniculitis. HPS was originally described by Risdall et al as a response to viral infections (4). Following the original report, HPS has been reported with bacterial, fungal, and viral infections. HPS also occurs in association with malignant neoplasmas, most often lymphoreticular neoplasms, which are usually of T-cell origin (5). The most consistent histopathologic feature in HPS is a proliferation of mature histiocytes that exhibit prominent erythrophagocytosis and cytophagocytosis. It has been reported that in HPS, the prominent phagocytic histiocytes are reactive and are stimulated by T cells (6). Furthermore, many of the findings in HPS may also be due directly or indirectly to cytokines produced by proliferating T-cell lymphocytes and reactive phagocytic histiocytes.
There is no objection that standard treatment strategy for malignant lymphoma includes aggressive chemotherapy. (12) (13) (14) . Recently, it has been reported that the presence of HPS and the expression of γ/δ Tcell receptors in tumor cells predict poor survival (15 
However, controlling HPS may become the key treatment for SPTCL; SPTCL has a high mortality rate despite the use of aggressive chemotherapy regimen, and in the majority of patients the mortality is a result of the complication of HPS and not to the lymphoma itself. As mentioned earlier, SPTCL is a T-cell origin and complicating HPS is due to
